El global biòpsia líquida mercat es va valorar 1.3 mil milions de dòlars in 2020. By 2031, it is estimated that it will reach 6.9 mil milions de dòlars. Això representa a 20.8% annual growth rate from 2022 to 2031.
Demanda creixent
Asia-Pacific is projected to experience significant growth over the 2022-2029 forecast period. This is due to rising government awareness programs, medical tourism, increasing research activities in Asia-Pacific, rising cancer cases, and the growing demand for quality healthcare.
Obteniu una mostra d'un informe per obtenir una visió completa @ https://market.us/report/liquid-biopsy-market/request-sample/
The country section of this report provides information on market-influencing factors and changes in domestic regulations that will impact market trends. To forecast the market for particular countries, data points like the downstream and the upstream value chain analysis as well as technology trends and porter’s five force analysis are used. Forecast analysis of country data also considers the presence and limitations of global brands and the challenges they face due to the competition from domestic and local brands.
Factors conductors
Over the forecast period, the main driving factors for the United States liquid biopsy market are the increase in patient preference and cancer patients.
Factors restrictius
However, market growth is expected to be hindered by the high costs associated with research and development professionals, the limited infrastructure facilities, and the lower sensitivity of liquid biopsies. The low reimbursement rate and low penetration of technology in developing countries will also be affected the market growth.
This market report on liquid biopsy provides detailed information about the latest developments, trade regulations, import-export analyses, production analysis, and value chain optimization. It also analyses the impact of localized market players. For more information on the liquid biopsy market, please contact Data Bridge Market Research. We will provide you with an Analyst Brief.
Desenvolupament recent
- Guardant Health, Inc. (US) introduced its Guardant360 response test, which detects changes in the circulating tumor DNA (ctDNA).
- F. Hoffmann-La Roche Ltd., Switzerland, received FDA approval in October 2020 for expanded claims to the Cobas EGFR Mutation Test v2 that can be used as a companion diagnosis (CDx) for a wider variety of therapies for non-small-cell lung carcinoma (NSCLC).
- Biocept, Inc. (US) reached an agreement with a California-based independent physician association (IPA) in March 2020 to provide Target Selector liquid biopsy testing services to doctors and patients within the network.
Empreses clau
- RainDanceTechnologies
- Biocartis
- Guardant Salut
- MDxHealth
- Pathway Genomics
- NeoGenomics Laboraories
- Sysmex Inostics
- Cynvenio
- Menarini Silicon Biosystems
- Qiagen
- Biotecnologies adaptatives
- Biocept
- Angle plc
Els segments clau del mercat
Tipus
- CTC
- ADNc
- Exosomes
Sol·licitud
- Blood Sample based
- Urine Sample based
- Bio Fluids based
Preguntes freqüents
- What are the most recent trends in the liquid biopsy?
- What are the most critical areas for liquid biopsy?
- Who are the major players in the liquid biopsy?
- Who are the top end users for liquid biopsy products & related services?
- Which region is the most lucrative for liquid biopsies?
Informe relacionat:
Global Breast Cancer Liquid Biopsy Market Factors de creixement de la indústria, tipus i aplicacions Anàlisi regional Jugadors clau i previsió per al 2031
Global Liquid Biopsy Products Market Recerca 2022 Segment de la indústria regional per producció Ingressos de consum amb vendes i taxa de creixement
Global Lung Cancer Liquid Biopsy Market Recerca 2022 Els actors clau de la mida de la indústria comparteixen l'anàlisi de tendències i les previsions de creixement fins al 2031
Global Breast Biopsy Device Market Per fabricants Regions Tipus de producte Aplicació i previsió fins al 2031
Sobre Market.us
Market.US (Powered by Prudour Private Limited) s'especialitza en investigacions i anàlisis en profunditat. Aquesta empresa ha demostrat ser una consultora líder i un investigador de mercat personalitzat i un proveïdor d'informes d'investigació de mercat molt respectat.
Detalls de contacte:
Equip de desenvolupament empresarial global: Market.us
Market.us (proporcionat per Prudour Pvt. Ltd.)
Adreça: 420 Lexington Avenue, Suite 300 Nova York, NY 10170, Estats Units
Telèfon: +1 718 618 4351 (Internacional), Telèfon: +91 78878 22626 (Àsia)
Correu electrònic: [protegit per correu electrònic]
QUÈ TREURE D'AQUEST ARTICLE:
- (US) reached an agreement with a California-based independent physician association (IPA) in March 2020 to provide Target Selector liquid biopsy testing services to doctors and patients within the network.
- Aquesta empresa ha demostrat ser una consultora líder i un investigador de mercat personalitzat i un proveïdor d'informes d'investigació de mercat molt respectat.
- Over the forecast period, the main driving factors for the United States liquid biopsy market are the increase in patient preference and cancer patients.
